Tumorigenicity studies of induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) for the treatment of age-related macular degeneration.
Basic studies of human pluripotential stem cells have advanced rapidly and stem cell products are now seeing therapeutic applications. However, questions remain regarding the tumorigenic potential of such cells. Here, we report the tumorigenic potential of induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) for the treatment of wet-type, age-related macular degeneration (AMD). First, immunodeficient mouse strains (nude, SCID, NOD-SCID and NOG) were tested for HeLa cells' tumor-forming capacity by transplanting various cell doses subcutaneously with or without Matrigel. The 50% Tumor Producing Dose (TPD50 value) is the minimal dose of transplanted cells that generated tumors in 50% of animals. For HeLa cells, the TPD50 was the lowest when cells were embedded in Matrigel and transplanted into NOG mice (TPD50 = 10(1.1), n = 75). The TPD50 for undifferentiated iPSCs transplanted subcutaneously to NOG mice in Matrigel was 10(2.12); (n = 30). Based on these experiments, 1×10(6) iPSC-derived RPE were transplanted subcutaneously with Matrigel, and no tumor was found during 15 months of monitoring (n = 65). Next, to model clinical application, we assessed the tumor-forming potential of HeLa cells and iPSC 201B7 cells following subretinal transplantation of nude rats. The TPD50 for iPSCs was 10(4.73) (n = 20) and for HeLa cells 10(1.32) (n = 37) respectively. Next, the tumorigenicity of iPSC-derived RPE was tested in the subretinal space of nude rats by transplanting 0.8-1.5×10(4) iPSC-derived RPE in a collagen-lined (1 mm×1 mm) sheet. No tumor was found with iPSC-derived RPE sheets during 6-12 months of monitoring (n = 26). Considering the number of rodents used, the monitoring period, the sensitivity of detecting tumors via subcutaneous and subretinal administration routes and the incidence of tumor formation from the iPSC-derived RPE, we conclude that the tumorigenic potential of the iPSC-derived RPE was negligible.
Division of Cell Therapy, Foundation for Biomedical Research and Innovation, Kobe, Japan ; Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology, Kobe, Japan.
Hoshimi
H
Kanemura
Division of Cell Therapy, Foundation for Biomedical Research and Innovation, Kobe, Japan.
Masahiro J
MJ
Go
Division of Cell Therapy, Foundation for Biomedical Research and Innovation, Kobe, Japan.
Masayuki
M
Shikamura
Division of Cell Therapy, Foundation for Biomedical Research and Innovation, Kobe, Japan.
Naoki
N
Nishishita
Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology, Kobe, Japan.
Noriko
N
Sakai
Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology, Kobe, Japan ; Department of Ophthalmology, Kawasaki Medical School, Kurashiki, Okayama, Japan.
Hiroyuki
H
Kamao
Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology, Kobe, Japan.
Michiko
M
Mandai
Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology, Kobe, Japan.
Chikako
C
Morinaga
Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology, Kobe, Japan.
Masayo
M
Takahashi
Division of Cell Therapy, Foundation for Biomedical Research and Innovation, Kobe, Japan ; Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology, Kobe, Japan.
Shin
S
Kawamata
D000818:Animals; D063646:Carcinogenesis; D005260:Female; D006367:HeLa Cells; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000166:cytology* / Q000637:transplantation*; D008268:Macular Degeneration / Q000473:pathology* / Q000628:therapy*; D051379:Mice; D051381:Rats; D055213:Retinal Pigment Epithelium / Q000166:cytology*; D033581:Stem Cell Transplantation / Q000009:adverse effects*